

# REMARKS

Upon entry of the present amendments, claims 1-21 are pending. The present amendment does not introduce new matter.

*Version With Markings to Show Changes*

3. (Amended) The mammal of claim 1 [or 2], whose cells further contain a polynucleotide, comprising:  
a second pancreas-specific promoter operably linked to an EGF-coding polynucleotide.
4. (Amended) The mammal of claim 1 [or 2], whose cells further contain a polynucleotide, comprising:  
an insulin promoter operably linked to an EGF-coding polynucleotide promoter.
7. (Amended) The method[s] of claim 5 [or 6], wherein the pancreatic source of KGF is provided by expression of a recombinant DNA molecule comprising a pancreatic specific promoter operably linked to a KGF-coding polynucleotide.
18. (New) A transgenic mouse having incorporated into its genome a polynucleotide sequence comprising a pancreas-specific promoter operably linked to a KGF-coding polynucleotide sequence, wherein said KGF-coding polynucleotide sequence is expressed in the pancreatic cells such that said mouse exhibits in its pancreas at least one of the following morphological changes selected from the group consisting of hyperproliferation of duct cells and disorganized growth of islet of Langerhans.
19. (New) A transgenic mouse having incorporated into its genome a polynucleotide sequence comprising a pancreas-specific promoter operably linked to an EGF-coding polynucleotide sequence, wherein said EGF-coding polynucleotide sequence is expressed in the pancreatic cells such that said mouse exhibits in its pancreas at least one of the following morphological changes selected from the group consisting of hyperproliferation of duct cells, disorganized growth of islet of Langerhans, and an increase number of intra-islet ductules.
20. (New) The transgenic mouse of claim 18 further comprising incorporated into its genome a polynucleotide comprising a pancreas-specific promoter operably linked to an


EGF-coding polynucleotide, wherein said EGF-coding polynucleotide and said KGF-coding polynucleotide is expressed in the pancreatic cells such that said mouse exhibits in its pancreas at least one of the following morphological changes selected from the group consisting of hyperproliferation of duct cells, disorganized growth of islet Langerhans, and increased number of intra-islet ductules, and extensive intra-islet fibrosis.

21. (New) The method of claim 6, wherein the pancreatic source of KGF is provided by expression of a recombinant DNA molecule comprising a pancreatic specific promoter operably linked to a KGF-coding polynucleotide.

## CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,520

Christina V. Karnakis, Reg. No. 45,899

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

TRADOC'S:1456797.1(V82L01!.DOC)